MarginsXMarginsX
Home › Markets › Health Care › MGTX

MeiraGTx Holdings plc (MGTX)

MGTX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.74
-4.79% on the day
Market cap
$854.2M
Small cap
Revenue · 2025
$81.4M
+144.6% on 2024
Net income · 2025
-$114.2M
-140.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/0001104659-26-036494-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMGTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2018
SEC CIK0001735438
SEC industry codeBiological Products, (No Diagnostic Substances)

Financials · 2025

LineValue
Revenue$81.4M
Net income-$114.2M
Operating income-$106.0M
Net margin-140.3%
Operating margin-130.2%
Revenue growth+144.6%
Cash$65.9M
Total assets$244.4M
P/E (computed)Net income was not positive
P/S (computed)10.5×

Warning signs

Cash runway
Cash-flow positive
$184.7M cash at September 30, 2026
Share count, 1 year
+21.4%
2025-10-28 to 2026-11-04 · +53.7% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$4.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$184.7M cash; operating cash flow $339K a quarter.Report 2026-09-30
Shares outstanding97,730,540 (2026-11-04); 80,490,889 a year earlier; 63,597,151 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-16
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Jericho, New York, United StatesPCAOB Form AP 2026-04-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$4.8M-$51.2M-$24.5M$184.7MNo debt tags$401.9M10-Q 2026-11-12
Q2 2026
2026-06-30
$321.4M$160.7M-$38.5M$143.2MNo debt tags$397.5M10-Q 2026-08-13
Q1 2026
2026-03-31
$293K-$46.3M$17.8M$71.5M$24.9M$79.8M10-Q 2026-05-14
Q4 2025
2025-12-31
$75.4M$15.1M$46.6M$65.9M$24.6M$81.4M10-K 2026-03-30
Q3 2025
2025-09-30
$410K-$50.5M-$12.2M$14.8M$74.1M$27.4M10-Q 2026-11-12
Q2 2025
2025-06-30
$3.7M-$38.8M-$43.9M$32.2MNo debt tags$37.9M10-Q 2026-08-13
Q1 2025
2025-03-31
$1.9M-$40.0M-$36.8M$66.5MNo debt tags$34.5M10-Q 2026-05-14
Q4 2024
2024-12-31
$21.4M-$39.4M-$23.3M$103.7MNo debt tags$33.3M10-K 2026-03-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-11-12
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 513 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.0%
1 month-7.6%
3 months-27.5%
Year to date+15.5%
1 year+11.1%
From 52-week high-38.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
IMTXImmatics N.V.$6.17-3.44%$923.2M
ODTXOdyssey Therapeutics Inc.$19.36+1.15%$930.6M
GLUEMonte Rosa Therapeutics Inc.$9.16-2.24%$782.7M
PRMEPrime Medicine Inc.$4.19-1.87%$762.3M
AURAAura Biosciences Inc.$7.22+1.55%$751.4M
SLDBSolid Biosciences Inc.$6.48-5.26%$723.2M
ATTOAttovia Therapeutics Inc.$14.72-2.68%$673.1M
DBVTDBV Technologies S.A.$10.27-6.76%$645.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier